Nurix therapeutics announces participation in the 2022 rbc capital markets global healthcare conference

San francisco, may 11, 2022 (globe newswire) -- nurix therapeutics, inc.  (nasdaq: nrix), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that arthur t. sands, m.d., ph.d., nurix's president and chief executive officer, will participate in a fireside chat at the 2022 rbc capital markets global healthcare conference on wednesday, may 18th, 2022 at 11:00 a.m. et.
NRIX Ratings Summary
NRIX Quant Ranking